Rating Change
HC Wainwright & Co. reiterated its Buy rating on ImmunityBio, Inc. (NASDAQ:IBRX) on October 15, 2026.
reiterateNASDAQ:IBRX
HC Wainwright & Co. Reiterates Buy Rating on ImmunityBio, Inc. (IBRX)
HC Wainwright & Co. reiterated its Buy rating on ImmunityBio, Inc.
At publication ·
What changed
ImmunityBio, Inc. (NASDAQ:IBRX) · reiterate
- Firm
- HC Wainwright & Co.
- Rating
- Buy to Buy
- Price at event
- $10.18
- Market capitalization
- $2.2B
At a glance
Key takeaways
- HC Wainwright & Co. maintained a Buy rating on ImmunityBio (IBRX) on October 15, 2026, with the stock trading at $10.18 and a market cap of $2.2 billion.
Market Context
ImmunityBio, Inc. operates in the Healthcare sector. The stock currently trades at $10.18 with a market capitalization of $2.2B. The stock has gained 299.6% over the past 52 weeks.
Analyst coverage from HC Wainwright & Co. provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for ImmunityBio, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for ImmunityBio, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 15, 2026 | HC Wainwright & Co. | Buy | N/A |
| Jun 02, 2026 | HC Wainwright & Co. | Buy | N/A |
| May 21, 2026 | BTIG | Buy | N/A |
| May 20, 2026 | HC Wainwright & Co. | Buy | N/A |
| May 05, 2026 | D. Boral Capital | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View IBRX Stock Page
Frequently Asked Questions
What does the Buy rating mean for IBRX?
A rating of Buy from HC Wainwright & Co. reflects the analyst's outlook on ImmunityBio, Inc. (NASDAQ:IBRX). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the IBRX forecast page.